Global Pharmacovigilance Market

Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical drugs market is expected to grow from $ 1,136.23 billion in 2022 to $1,199.86 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The pharmaceutical drugs market is expected to reach $1,848.49 billion in 2027 at a CAGR of 11.4%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drug market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates rose to 3.5% by 2021. These factors are expected to hurt the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed, and grass. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. North America was the largest region in the pharmaceutical drugs market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations

Pharmaceutical contract development and manufacturing refers to a business that offers services for drug research and manufacture within the pharmaceutical sector. Using CDMOs as a partner, pharmaceutical companies can outsource medication development and production. Full-service drug development and manufacturing outsourcing companies (CDMOs) can handle every stage of the process and work with clients that want to outsource specific steps in their workflow. Everything is based on the requirements of each client. The main types of pharmaceutical contract development and manufacturing organisations (CMO) are active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, and secondary packaging. The active pharmaceutical ingredient (API) manufacturing includes the manufacturing of the part of any drug that produces the desired effects. The various research phases include preclinical, phase I, phase II, phase III, and phase IV. The different end-use sectors include big pharmaceutical companies, generic pharmaceutical companies, and small & medium-sized pharmaceutical companies. The pharmaceutical contract development and manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing market statistics, including pharmaceutical contract development and manufacturing industry global market size, regional shares, competitors' pharmaceutical contract development and manufacturing market share, detailed pharmaceutical contract development and manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing industry. This pharmaceutical contract development and manufacturing market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical contract development and manufacturing market grew from $122.31 billion in 2022 to $130.82 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical contract development and manufacturing market is expected to grow from $196.53 billion in 2027 at a CAGR of 10.7%. The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and raise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand for pharmaceutical contract development and manufacturing market. According to Alkermes PLC., a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost-cutting. The pharmaceutical contract development and manufacturing market are restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production. The low production output results in low revenue generation for the production unit, affecting the overall pharmaceutical contract development and manufacturing market. For instance, in January 2020, according to an article shared by Economic Times, an India-based English-language business-focused daily newspaper, The 1,500 API manufacturing facilities in India, according to the country's drug regulatory organisation, are only operating at 40% of their potential. Therefore, the usage of capacity of the production plant negatively affects the pharmaceutical contract development and manufacturing market. The companies in the pharmaceutical contract development and manufacturing market are investing in acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition to expand their global market reach to meet the client needs, increase their production capabilities while maintaining cost efficiencies, and get access to the latest technology and new services. The high levels of merger and acquisition activities are resulting in the consolidation of the contract service providers. For instance, in July 2022, Pharma Nobis, a US-based provider of contract manufacturing and private label services, acquired Fagron’s U.S. contract manufacturing business for an undisclosed amount. Through this acquisition, Pharma Nobis is expected to offer contract manufacturing and private label services to American retailers and consumer healthcare corporations. 20% of the company will continue to be owned by Fagron. In August 2022, Catalent, Inc., a US-based provider of delivery technologies, development, and drug manufacturing, acquired Metrics Contract Services for $475 million. This acquisition is expected to improve Catalent's ability to work with highly potent chemicals while enhancing its expertise in integrated oral solid formulation research, production, and packaging to assist clients in streamlining and accelerating their processes. Metrics Contract Services is a US-based pharmaceutical contract development and manufacturing organization. Major players in the pharmaceutical contract development and manufacturing market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH, Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V., Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd., AbbVie Inc., Consort Medical PLC., Almac Group, Siegfried Holding AG, Evonik Industries AG, and Vetter Pharma International GMBH. North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the global pharmaceutical contract development and manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical contract development and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical contract development and manufacturing market includes revenues earned by entities by providing drug development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pharmaceutical contract development and manufacturing organisation (CMO) market is segmented - 1) By Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging 2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV 3) By End-User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies

Pharmaceutical packaging equipment refers to the equipment comprised of multiple equipment and its components, piping, instruments, electrical items and other related accessories which are all fabricated and assembled at the shop and usually mounted on the skid which are ready for connection and used for packaging of all pharmaceutical products, using flexible, and heat sealable material to form packages that are filled with a product and then sealed. The main types of products of pharmaceutical packaging equipment are primary packaging equipment, secondary packaging equipment, and labeling and sterilization equipment. Primary packaging equipment is in direct contact with the product itself and is referred to as a consumer unit. Primary packaging is what directly encases and contains the drug product. Secondary packaging equipment provides corrugated cardboard packaging print finished to a high standard. Secondary packaging is the exterior packaging of the primary packaging that groups packages and further protects or labels the drug product. Labeling and sterilization equipment is responsible for adding directions of use and sterilizing the packaging environment. The various types of pharmaceutical packaging equipment are blenders, granulators, tablet pressers, tablet coating machines, and allied machines. The pharmaceutical packaging equipment market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical packaging equipment market statistics, including pharmaceutical packaging equipment industry global market size, regional shares, competitors with a pharmaceutical packaging equipment market share, detailed pharmaceutical packaging equipment market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical packaging equipment industry. This pharmaceutical packaging equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pharmaceutical packaging equipment market size grew from $9.94 billion in 2022 to $11.06 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical packaging equipment market size is expected to grow to $16.34 billion in 2027 at a CAGR of 10.2%. An increase in ageing population is expected to increase the prevalence of age-related ailments, thus contributing to the growth of the pharmaceutical drugs and pharmaceutical packaging equipment market. The elderly population is increasing rapidly across the world, and it is expected to continue over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) report, the population aged 65 years and above is expected to reach approximately 71 million by 2030 and 98 million by 2060 in the USA. It is estimated by 2030, China will have nearly half of the Parkinson’s disease population in the world, which can be attributed to the country’s aging population. This expected increase in the aging population suffering from age-related ailments is projected to drive the pharmaceutical packaging equipment market. The automatic packaging machine is increasingly utilized in the pharmaceutical packaging equipment market. The machine automatically supplies packing materials and contents, and other machines of the packaging process can be done automatically. For instance, in July 2020, OPTIMA Packaging Group, a Germany based company that designs and builds packaging equipment for pharmaceutical, consumer, nonwovens, and life science products, launched OPTIMA FPA. It is a unique platform that can assemble pen injectors both fully or semi-automatically. It is especially suitable as an entry-level system. Another new feature of the Optima FPA is the choice of adding a printer connected with 360-degree labeling. This product launch has increased the company’s automated packaging solutions portfolio. In February 2021, ProMach, a US-based packaging machinery company, acquired Serpa Packaging Solutions for an undisclosed amount. The addition of Serpa brings automated cartoning systems into ProMach’s portfolio and significantly expands ProMach’s specialized secondary packaging machinery and line integration capabilities for the rapidly growing pharmaceutical industry. Serpa Packaging Solutions is a US-based company that designs and manufactures pharmaceutical packaging equipment. Major players in the pharmaceutical packaging equipment market are Körber AG, Uhlmann Group, Marchesini Group S.p.A., Optima Packaging Group, Romaco Holding GmbH, MG2 s.r.l., Robert Bosch GmbH, Industria Macchine Automatiche S.p.A., Vanguard Pharmaceutical Machinery, Accutek Packaging Equipment Companies, MULTIVAC Group, Bausch + Ströbel Maschinenfabrik Ilshofen GmbH + Co. KG, ACG Group, Coesia S.P.A., Syntegon Technology, Trustar Pharma & Packing Equipment, Inline Filling Systems, Dara Pharmaceutical Packaging, ARPAC LLC, Romaco Group, N.K.P. Pharma, Ropack, and Trustar Pharma & Packing Equipment. North America was the largest region in the pharmaceutical packaging equipment market in 2022. Asia-Pacific was the second-largest market in the pharmaceutical packaging equipment market. The regions covered in the pharmaceutical packaging equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharmaceutical packaging equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pharmaceuticals packaging equipment market consists of sales of accumulating and collating machines, blister packs, skin packs and vacuum packaging machines, bottle caps equipment, over-capping, lidding, closing, seaming and sealing machines, box, case, tray, and carrier forming, packing, unpacking, closing, and sealing machines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical packaging equipment market is segmented - 1) By Product: Primary Packaging Equipment, Secondary Packaging Equipment, Labelling And Sterialization Equipment 2) By Packaging Type: Liquids Packaging Equipment, Solid Packaging Equipment, Semi-Solid Packaging Equipment 3) By Equipment Type: Blenders, Granulators, Tablet Pressers, Tablet Coating Machine, Allied Machines 4) By Mode of Administration: Injectable Administration, Topical Administration, Oral Administration

Pharmaceutical excipients refer to components of a drug delivery system that are not active pharmaceutical ingredients (API) but have undergone acceptable safety evaluation. Excipients, which are not active themselves, allow the drug ingredient to be administered to the patient in the proper form and support the mode and site of action. The main types of products in pharmaceutical excipients are inorganic chemicals and organic chemicals. The pharmaceutical inorganic chemical industry is concerned with the manufacture, physical or chemical characteristics of substances, assay techniques, and applications of inorganic substances used as pharmaceutical aids, treatments, and diagnostics. The different functionalities include fillers and diluents, suspending and viscosity agents, coating agents, bindeflavoringring agents sweetenersners, disintegrants, colorants, lubric, ants, and glidants, and others and involve various formulations such as oral formulation, topical formulation, and parental formulation. The pharmaceutical excipients market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical excipients market statistics, including pharmaceutical excipients industry global market size, regional shares, competitors with a pharmaceutical excipients market share, detailed pharmaceutical excipients market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical excipients industry. This pharmaceutical excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical excipients market grew from $8.6 billion in 2022 to $9.11 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical excipients market is expected to grow from $11.55 billion in 2027 at a CAGR of 6.1%. The global surge in the sale of generic drugs contributed to the growth of the pharmaceutical excipients market. Generic drugs are alternatives to the marketed brand-name drug in the same dosage form, safety, strength, route of administration, and quality. According to India Brand Equity Foundation (IBEF), India is the largest provider of generic medicines, the country’s generic drugs account for 20% of the global generic drug exports. Indian pharmaceutical companies received 300 generic drug approvals in the USA. The surge in the demand for generic drugs drives the pharmaceutical excipients market. Concerns related to safety and quality are expected to limit the growth of the pharmaceutical excipients market. According to the Pharmaceutical Journal, there are certain complications in children with the use of pharmaceutical drugs with excipients. For instance, the colourants used in medicine as colouring agents may lead to sensitivity reactions and hyperactive behaviour in children. Ethanol is another solvent that is widely used in an oral liquid formulation, the use of ethanol mixed medicine for children may have a risk of acute intoxication when overdose, and it may lead to chronic toxicity with long-term use. Concerns related to safety and quality are expected to limit the growth of the pharmaceutical excipients market. The increase in research and development in pharmaceutical formulation to enhance the production process and product quality by using multi-functional excipients is a trend shaping the market. Excipients play a significant role in helping pharmaceutical manufacturers better support patients by increasing compliance and treatment effectiveness. For instance, Evonik’s newly launched EUDRAGIT FS 100 is a solid version of the existing EUDRAGIT FS 30 D. This new multi-functional version allows pharmaceutical companies to use the polymer in many new applications, such as hot-melt extrusion, solvent spray-drying, and solvent coating, which was impossible to achieve in past decades where only the aqueous version was available. In July 2021, Philip Morris International, a US-based cigarette and tobacco manufacturing company acquired Fertin Pharma for $820m. Through this acquisition, PMI will gain significant ability in developing, formulating, and marketing existing as well as new smoke-free platforms. Fertin Pharma is a Denmark-based company that manufactures pharmaceutical excipients. Major players in the pharmaceutical excipients market are, Archer Daniels Midland Co., Associated British Foods, Dow Chemical Company, Evonik, Croda International PLC., Ashland, BASF SE, The Lubrizol Corporation, and Roquette Frères. North America is the largest region in the pharmaceutical excipients market in 2022. Middle East is expected to be the fastest growing region in the global pharmaceutical excipients market during the forecast period. The regions covered in the global pharmaceutical excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical excipients market consists of sales of microcrystalline cellulose, stearic acid, gelatin, and tartaric acid. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical excipients market is segmented - 1) By Functionality: Fillers And Diluents, Suspending And Viscosity Agents, Coating Agents, Binders, Flavouring Agents And Sweetners, Disintegrants, Colorants, Lubricants And Glidants, Other Functionalities 2) By Type Of Formulation: Oral Fromulation, Topical Formulation, Parental Formulation 3) By Product: Inorganic Chemicals, Organic Chemicals

The pharma microbiology testing kits detect contamination and uphold good standards. They are used to detect the microbial limits among drugs, vaccines, and other biologics. The main products of pharma microbiology testing kits are consumables and equipment. The pharma microbiology testing kits consumables are products used to detect the microbial limits among drugs, vaccines, and other biologics. The various tests performed by pharma microbiology testing kits are endotoxin testing, sterility testing, microbial examination, environmental monitoring, and others that are used by end-users such as hospitals and diagnostic centres, custom lab service providers, and academic and research institutes. The pharma microbiology testing kits market research report is one of a series of new reports from The Business Research Company that provides pharma microbiology testing kits market statistics, including pharma microbiology testing kits industry global market size, regional shares, competitors with a pharma microbiology testing kits market share, detailed pharma microbiology testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the pharma microbiology testing kits industry. This pharma microbiology testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pharma microbiology testing kits market grew from $5.66 billion in 2022 to $6.25 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharma microbiology testing kits market is expected to grow from $8.78 billion in 2027 at a CAGR of 8.8%. The rise in the incidence of infectious diseases is one of the prime drivers of the pharma microbiology testing kits market. According to CDC (Centre for Disease Control and Prevention), infectious diseases such as Hepatitis A, B, and C, sexually transmitted diseases (STDs), and human immunodeficiency virus (HIV) are increasing their prevalence globally. WHO report indicated that there were about 1.4 million cases of Hepatitis A reported globally every year. Hence the increasing number of infectious disease cases due to infected needle injections, unprotected sex, homelessness, lack of access to medical care, and other socioeconomic challenges drive the pharma microbiology testing kits market. The limited shelf life of microorganisms and microbiology reagents acts as a major restraint on the pharma microbiology testing kits market. Shelf life is defined as the time for which a product remains fit for use after its generation. The shelf life of microbiology reagents depends upon exposure to atmospheric conditions. The life of microorganisms such as bacteria (only 12hours) is short therefore the time for microbiological research is very limited as the quality of microorganisms deteriorates and becomes unfit to use resulting in inaccurate pharma microbiology testing kits results. Hence, the short or limited shelf life of microbiology reagents may increase cost and hamper the pharma microbiology testing kits market growth. Outsourcing of microbiological testing to contract testing laboratories is becoming popular in the pharma microbiology testing kits market. Outsourcing of routine microbiological testing activities controls and ensures better quality and safety of raw materials, intermediates, and finished products. The contract testing laboratories are outsourced with some testing areas such as stability testing, raw material testing, method validation, microbial testing, environmental monitoring, physical characterization, batch-release testing, bioanalytical testing, and others. For instance, the global healthcare analytical testing market is projected to expand to $4.13 billion by 2021 at a growth rate of 11.3%. Food and Drug Administration (FDA) is a federal agency and regulatory body for the pharma microbiology testing kits market in the United States department of health and human services. Laboratories and food companies across the globe use these standards to make sure that food products are safe to eat and drink. FDA's Bacteriological Analytical Manual (BAM) detects pathogens (bacterial, viral, parasitic, plus yeast and mold) in food and cosmetic products. Enhanced standards for microbial testing, additional microbiological methods, and environmental testing methods have been set by FDA to ensure food and drug safety. In November 2022, IDEXX, a US-based healthcare innovation company, acquired Tecta-PDS for an undisclosed amount. The acquisition would allow IDEXX to expand its footprint in water microbiology testing. Tecta-PDS is a Canada-based water microbiology testing company. Major players in the pharma microbiology testing kits market are F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Abbott Laboratories, ThermoFisher Scientific, Lucideon, SGS SA, ToxiKon, Pace Analytical Services, Boston Analytics, Charles River Laboratories International, and Nelson Laboratories. North America was the largest region in the pharma microbiology testing kits market in 2022. Western Europe was the second largest region in the global pharma microbiology testing kits market report. The regions covered in the global pharma microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharma microbiology testing kits market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The pharma microbiology testing kits market consists of sales of rapid test systems, common rapid test kits, rapid tests for salmonella, PCR test, and lateral flow. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharma microbiology testing kits market is segmented - 1) By Product: Consumables, Equipment 2) By Test: Endotoxin Testing, Sterility Testing, Microbial Examination, Environmental Monitoring, Other Tests 3) By End User: Hospitals & Diagnostic Centers, Custom Lab Service Providers, Academic & Research Institutes

Pharmaceutical sterility testing refers to a test that is intended to show if biological parenterals made for human use contain extraneous, viable contaminating microorganisms or not. All pharmaceutical items used on patients by medical professionals must be of the highest quality and extremely safe.Otherwise, it could harm the patients. Testing for sterility assures that the offered product is suitably sterile. The main types of pharmaceutical sterility testing are in-house and outsourced. The various types of tests include sterility testing, bioburden testing, and bacterial endotoxin testing, which are used to test sterile drugs, medical devices, biologics, and therapeutics. An in vitro assay for detecting bacterial endotoxins is known as a bacterial endotoxin test. The bacterial endotoxin test detects bacterial endotoxins by lysing blood cells from horseshoe crabs. The different products used are instruments, kits and reagents, and services. The pharmaceutical sterility testing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical sterility testing market statistics, including pharmaceutical sterility testing industry global market size, regional shares, competitors with a pharmaceutical sterility testing market share, detailed pharmaceutical sterility testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical sterility testing industry. This pharmaceutical sterility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical sterility testing market grew from $1.19 billion in 2022 to $1.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2027 at a CAGR of 12.5%. An increase in the number of drug launches and rising investment in research and development (R&D) contributed to the growth of the market. Sterility is an important step in the manufacture of drugs to avoid product contamination and make the drugs free from any viable microorganisms. For instance, in March 2022, according to an article shared by Pharmaceutical Technology, a US-based independent source for information, insight, and analysis on bio/pharmaceutical formulation, the UK government has announced a $347 million (£260 million) commitment to advance research and development (R&D) and the creation of innovative treatments, tools, and diagnostics. Additionally, in December 2021, according to a report shared by IQVIA, a US-based provider of advanced analytics, technology solutions, and clinical research services, Over the next five years, until 2026, a total of 300 new medications are anticipated to be introduced; this is a large increase over the level observed on average over the previous ten years, and the drugs are anticipated to tilt toward specialty, niche, and orphan drugs. In the next five years, there will be a $196 billion increase in spending on new products, which will be roughly offset by a $188 billion decrease in brand spending owing to loss of exclusivity. Companies in the pharmaceutical testing market are introducing new pharmaceutical sterility testing products and services to enhance their product portfolio and increase their presence in the market. The companies are launching technologically superior outcomes and well-equipped services to utilize the growth potential of the rising pharmaceutical sterility market. For instance, in June 2022, STEMart, a US-based provider of integrated medical device CRO services, launched comprehensive microbiology and sterility testing for sterile, non-pyrogenic products. A variety of services are included in comprehensive microbiology and sterility testing, such as the Antibiotic Potency Test to evaluate the bioactivity or potency of specific antibiotics for medical devices. Major players in the pharmaceutical sterility testing market are Pacific Biolabs, STRERIS Corporation, Boston Analytical, Gibraltar Laboratories, Sartorius AG, Solvias AG, SGS AG, Toxikon Inc., Pace Analytical Services LLC., Charles River Laboratories International Inc., Nelson Laboratories Inc., Rapid Micro Biosystems Inc., BioMerieux, Merck KGaA, Wuxi AppTec, Sotera Health LLC., Dynalabs, and Infinity. North America was the largest region in the pharmaceutical sterility testing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical sterility testing market during the forecast period. The regions covered in the global pharmaceutical sterility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical sterility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical sterility testing market includes revenues earned by entities by membrane filtration, direct transfer (product immersion), and product flush. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global pharmaceutical sterility testing market is segmented - 1) By Sample: Sterile Drugs, Medical Devices, Biologics, and Therapeutics 2) By Product Type: Instruments, Kits and Reagents, Services 3) By Type: In-House, Outsourcing 4) By Test Type: Sterility Testing, Bioburden Testing, and Bacterial Endotoxin Testing 5) By End- User: Compounding Pharmacies, Medical Devices Companies, Pharmaceutical Companies

Pharmaceutical active pharmaceutical ingredients (API) manufacturing refers to the production of the active substances that give a pharmaceutical medicine its desired impact on the body to treat a condition. Chemical components must be processed in order to make APIs. A biologic drug's active component is referred to as a bulk process intermediate. The main therapy areas of pharmaceutical API manufacturing are cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs, and other therapeutics uses. Cardiovascular diseases are a group of heart and blood vessel disorders. The various API type include chemical API and biological API that are used to produce innovative drugs, generic prescription drugs, and over-the-counter (OTC) drugs. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical active pharmaceutical ingredients (API) manufacturing market statistics, including pharmaceutical active pharmaceutical ingredients (API) manufacturing industry global market size, regional shares, competitors with a pharmaceutical active pharmaceutical ingredient (API) manufacturing market share, detailed pharmaceutical active pharmaceutical ingredients (API) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical active pharmaceutical ingredients (API) manufacturing industry. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical api manufacturing market grew from $195.29 billion in 2022 to $209.93 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical api manufacturing market is expected to grow from $266.72 billion in 2027 at a CAGR of 6.2%. The rise in the aging population is one of the major drivers of the pharmaceutical API manufacturing market. As the aging population increases, the demand for pharmaceutical drugs also increases. API acts as a specialty drug in these medicines to cure a particular disease. For instance, in October 2022, according to an article shared by WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, 80% of senior citizens will reside in low- and middle-income nations by 2050. The population is aging considerably more quickly than in the past. In 2020, there will be more persons over the age of 60 than under five-year-olds. Therefore, rise in aging population is driving the growth of the pharmaceutical API manufacturing market. Stringent regulations for approval of pharmaceutical drugs act as a restraint on the pharmaceutical API manufacturing market. Various regions have their own set of rules, guidelines, and regulations set by their respective drug regulatory bodies. For example, in Japan, the manufacturers have to register an API with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) through the country’s Drug Master File (DMF) system. Products like APIs and new excipients i.e. inactive substances used in a drug should be registered compulsorily. The API manufacturer is also responsible for DMF registration, even if they don't have their office in Japan. They should appoint an in-country caretaker (ICC) to apply on their behalf. Also, if there are any changes to be made to DMF products, either an application for change in registration or a minor change notification should be submitted by the ICC to the PMDA. This whole process delays the drug approvals, thereby negatively affecting the pharmaceuticals API manufacturing market. Many companies use modern technologies such as process control, and powder handling to optimize API manufacturing. These technologies include advances in Lyophilization i.e. freeze-drying process. It is a low-temperature dehydration process that involves freezing the product, lowering pressure, and then removing the ice formed. For instance, Telstar, a company that manufactures efficient integrated systems for pharmaceutical and manufacturing processes, developed LyoGistics Zero, automatic loading and unloading system for freeze dryers to manufacture hazardous products. The system uses a linear magnetic driving mechanism that functions without racks and belts to reduce particle generation and this improves the hygiene in API manufacturing. Also, ILC Dover, a pharmaceutical company, developed the JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders so that they can be mixed better in a solution. In March 2021, Piramal Pharma Ltd., an India-based healthcare solutions company, acquired Hemmo Pharmaceuticals for an amount of $105.8 million. This acquisition is expected to expand PPS’s capacity to provide integrated services to its clients globally by gaining access to the expanding peptide API industry. The deal would also increase peptide API manufacturing and development capabilities. Hemmo Pharmaceuticals is an India-based developer and manufacturer of peptide APIs. Major players in the pharmaceutical API manufacturing market are Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, PfizerInc., Aurobindo Pharma, Novartis AG, Dr. Reddy's Laboratories, Merck & Co.Inc., BASF SE., Bayer Healthcare, Mylan N.V., Albemarle Corporation, Actavis PLC., Hospira Inc., Ranbaxy Laboratories, Virbac, Zoetis, Heska Co., AbbVie Inc., AstraZeneca PLC., Eli Lilly and Company, GlaxoSmithKline PLC., Sanofi, Bristol-Myers Squibb, CiplaInc., and F. Hoffmann-La Roche Ltd. North America was the largest region in the pharmaceutical API manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical API manufacturing market during the forecast period. The regions covered in the global pharmaceutical API manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical API manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market includes tablet, capsule, cream, and injectable sales.Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pharmaceutical api manufacturing market is segmented - 1) By Therapy Area: Cardiovascular disorders, Metabolic disorders, Neurological disorders, Oncology, Musculoskeletal disorders, NSAIDs, Other therapeutics uses 2) By API Type: Chemical API, Biological API 3) By Drug Type: Innovative Drugs, Generic Prescription, Over-the-counter (OTC) Drugs

AI in pharma refers to the use of automated algorithms to jobs that normally need human intelligence. Large datasets including disease patterns can be successfully identified by AI solutions in pharma, and they can also assist in understanding which medication formulations would be most effective for treating certain ailments. The artificial intelligence (AI) in the pharma market covered in the report is segmented by technology into context-aware processing, natural language processing, querying method, and deep learning; by drug type into the small molecule, large molecules; by application into diagnosis, clinical trial research, drug discovery, research and development, epidemic prediction. The artificial intelligence (AI) in pharma market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) in pharma market statistics, including artificial intelligence (AI) in pharma industry global market size, regional shares, competitors with artificial intelligence (AI) in pharma market share, detailed artificial intelligence (AI) in pharma market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in pharma industry. This artificial intelligence (AI) in pharma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global AI in pharma market size grew from $1.24 billion in 2022 to $1.64 billion in 2023 at a compound annual growth rate (CAGR) of 32.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The AI in pharma market size is expected to grow to $4.61 billion in 2027 at a CAGR of 29.4%. The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10–15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs. For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startupInsilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market. A lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2022, according to the report published by UNLEASH, a UK-based digital media platform, IBM, and Morning Consult conducted surveys of more than 1,000 tech job seekers, more than 600 tech workers, and more than 300 tech recruiters in the UK, Spain, and Germany to determine the AI skills gap in Europe and found around 28% of recruiters report having difficulty locating candidates with deep learning, machine learning, and data engineering and analytics experience. The shortage of AI skills is seen as a major barrier to the pace of technology’s adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market. Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization, and process automation. For instance, in August 2022, Sanford Health, a US-based non-profit, integrated healthcare delivery system,and Sharp HealthCare, a US-based non-profit organization in healthcarepartnered with Dandelion Health, a US-based healthcare artificial intelligence (AI) company, introduced a comprehensive data platform that gives health institutions access to high-quality, representative patient data for clinical AI development. The Dandelion Platform is made to give health AI developers secure, ethical access to patient datasets which includes include images, waveforms, and structured health records, so they may make tools and products that will help patients and clinicians. In October 2021, Nurosene Health Inc., a Canada-based company focused on delivering innovative AI-based technology solutions that support mental performance and wellness acquired Netramark Incorporated for an undisclosed amount. Through this acquisition, Nurosene Health Inc aims to strengthen its capabilities in AI-based neuroscience product offerings. Netramark Incorporated is a Canada-based pharma tech company that utilizes AI, novel mathematical methods, and quantum computing to optimize new drug development, clinical trials, treatment, and diagnosis. Major players in the AI in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Inc., Exscientia, and Cyclica. North America was the largest region in the AI in pharma market in 2022. The regions covered in the AI in pharma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the AI in pharma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The AI in pharma market includes revenues earned by entities by implementing quality control, addressing supply chain problems in the production line, and minimising material waste. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ai in pharma market is segmented - 1) By Technology: Context-Aware Processing, Natural Language Processing, Querying Method, Deep Learning 2) By Drug Type: Small Molecule, Large Molecules 3) By Application: Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development, Epidemic Prediction